Skip to main content
. Author manuscript; available in PMC: 2013 May 1.
Published in final edited form as: J Cell Physiol. 2012 May;227(5):1805–1813. doi: 10.1002/jcp.22904

Fig. 5. Ad.mda-7 displays an enhanced antitumor response in prostate cancer cells overexpressing sCLU.

Fig. 5

Tumor xenografts from Vec Con-DU-145 and sCLU-DU-145 cells established in the left flanks of athymic nude mice were injected with phosphate-buffered saline (PBS) (control) or with the indicated Ad over a 4-wk period (total of seven injections). (A) Measurements of tumor xenograft volumes at different time points: average volume (minimum of five mice in each group), mean ± S.D. (*P< 0.05 between the indicated groups). (B) Photograph of the excised xenografted tumor with measurement of tumor weight at the end of the study; columns, mean (at least five mice in each group) ± S.D. sCLU and nCLU levels (C) and Caspase-Glo(R) 3/7 assay analyses for caspase-3 expression (D) were measured in tumor tissue lysates. The data expressed in the graph was the mean ± S.D. of three independent experiments. *, P < 0.05 vs. control and Ad.vec group; **, P < 0.05 vs. Vec Con-DU-145 Ad.mda-7-infected group.